Industry Segment Information (Tables)

6 Months Ended

Jun. 30, 2024

Segment Reporting [Abstract]

Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations

Revenue and operating income (loss) from continuing operations by reportable segment are shown in the table below:  

	Three Months Ended				Six Months Ended
	June 30, 2024		July 2, 2023		June 30, 2024		July 2, 2023
	(In thousands)
Revenues
Life Sciences	$	313,847	$	336,353	$	616,884	$	664,794
Diagnostics	378,045		372,919		725,137		719,549
Revenue purchase accounting adjustments	(207)		(206)		(416)		(412)
Total revenues	$	691,685	$	709,066	$	1,341,605	$	1,383,931
Segment Operating Income
Life Sciences	$	112,401	$	127,759	$	214,126	$	257,218
Diagnostics	97,915		85,241		173,345		159,673
Corporate	(11,449)		(8,707)		(22,810)		(23,404)
Subtotal reportable segments adjusted operating income	198,867		204,293		364,661		393,487
Amortization of intangible assets	(90,620)		(92,758)		(181,858)		(184,569)
Purchase accounting adjustments	(623)		(2,891)		(7,245)		(1,977)
Acquisition, divestiture and rebranding costs	(5,779)		(28,579)		(17,241)		(46,530)
Significant litigation matters and settlements	(6,276)		—		(6,276)		—
Significant environmental matters	—		—		—		(1,132)
Restructuring and other, net	(9,845)		(2,009)		(22,201)		(5,104)
Operating income from continuing operations	85,724		78,056		129,840		154,175
Interest and other (income) expense, net (see Note 4)	(938)		6,502		8,629		53,181
Income from continuing operations before income taxes	$	86,662	$	71,554	$	121,211	$	100,994